Tsai J C, Guy R H, Thornfeldt C R, Gao W N, Feingold K R, Elias P M
Cellegy Corporation, Novato, CA, USA.
J Pharm Sci. 1996 Jun;85(6):643-8. doi: 10.1021/js950219p.
The intercellular domains of the stratum corneum, which contain a mixture of cholesterol, free fatty acids, and ceramides, mediate both the epidermal permeability barrier and the transdermal delivery of both lipophilic and hydrophilic molecules. Prior studies have shown that each of the three key lipid classes is required for normal barrier function. For example, selective inhibition of either cholesterol, fatty acid, or ceramide synthesis in the epidermis delays barrier recovery rates after barrier perturbation of hairless mouse skin in vivo. In this study, we investigated the potential of certain inhibitors of lipid synthesis to enhance the transdermal delivery of lidocaine or caffeine as a result of their capacity to perturb barrier homeostasis. After acetone disruption of the barrier, the extent of lidocaine delivery and the degree of altered barrier function paralleled each other. Moreover, the further alteration in barrier function produced by either the fatty acid synthesis inhibitor 5-(tetradecyloxy)-2-furancarboxylic acid (TOFA), the cholesterol synthesis inhibitor fluvastatin (FLU), or cholesterol sulfate (CS) resulted in a further increase in lidocaine absorption. Furthermore, coapplications of TOFA and CS together caused an additive increase in lidocaine uptake. Finally, a comparable increase in drug delivery occurred when the barrier was disrupted initially with DMSO instead of acetone; coapplications of TOFA and FLU together again delayed barrier recovery and increased drug delivery by about 8-fold vs delivery from a standard enhancing vehicle. Whereas these metabolic inhibitors also variably increased the octanol/water partitioning of the drugs studied (perhaps via complexion or pH alterations), physicochemical effects of the inhibitors alone did not alter drug uptake in intact skin; i.e., passive mechanisms alone cannot account for the net increase in drug delivery. Our results show that modulations of epidermal lipid biosynthesis, following application of conventional, chemical penetration enhancers, cause a further boost in drug delivery, attributable to the ability of these agents to alter both permeability barrier homeostasis and thermodynamics. This biochemical/metabolic approach provides a novel means to enhance transdermal drug delivery in conjunction with the concurrent or prior use of chemical enhancers.
角质层的细胞间区域含有胆固醇、游离脂肪酸和神经酰胺的混合物,介导表皮渗透屏障以及亲脂性和亲水性分子的透皮递送。先前的研究表明,这三种关键脂质类别中的每一种对于正常屏障功能都是必需的。例如,在体内对无毛小鼠皮肤进行屏障破坏后,表皮中胆固醇、脂肪酸或神经酰胺合成的选择性抑制会延迟屏障恢复速率。在本研究中,我们研究了某些脂质合成抑制剂由于其扰乱屏障稳态的能力而增强利多卡因或咖啡因透皮递送的潜力。在用丙酮破坏屏障后,利多卡因递送的程度和屏障功能改变的程度相互平行。此外,脂肪酸合成抑制剂5-(十四烷氧基)-2-呋喃羧酸(TOFA)、胆固醇合成抑制剂氟伐他汀(FLU)或硫酸胆固醇(CS)对屏障功能的进一步改变导致利多卡因吸收进一步增加。此外,TOFA和CS共同应用导致利多卡因摄取呈加性增加。最后,当最初用二甲基亚砜而不是丙酮破坏屏障时,药物递送出现了类似的增加;TOFA和FLU共同应用再次延迟了屏障恢复,并使药物递送比从标准增强载体递送增加了约8倍。虽然这些代谢抑制剂也不同程度地增加了所研究药物的辛醇/水分配系数(可能是通过络合或pH改变),但抑制剂单独的物理化学作用并没有改变完整皮肤中的药物摄取;即,仅被动机制不能解释药物递送的净增加。我们的结果表明,在应用传统化学渗透促进剂后,表皮脂质生物合成的调节会进一步促进药物递送,这归因于这些药剂改变渗透屏障稳态和热力学的能力。这种生化/代谢方法提供了一种新的手段,可与化学促进剂的同时或先前使用相结合来增强透皮药物递送。